Tracey J Brown 11th Australian Peptide Conference 2015

Tracey J Brown

Dr Tracey Brown has had a career in biomedical research and biotechnology spanning 30 years with experience in the translation of preclinical findings into clinical applications associated with the glycosaminoglycan, hyaluronan (HA). Since completion of her doctorate in carbohydrate biochemistry at the Monash University, Melbourne Australia, Dr Brown has worked in several cancer institutes in both USA and Australia where she gained valuable experience in translational research. In 1999 Dr Brown commenced a research program focused on both the basic and the translational science surrounding the use of HA as a CD44-targeted drug delivery vehicle which actively transports chemotherapeutic drugs to solid tumours; this research culminated in the invention of the HyACT® platform technology. To date Tracey and her team have developed eight anti-cancer agents of which three have entered human clinical trials with the lead drug currently being evaluated in a global pivotal Phase lll. In 2006, the Australian biotechnology company, Alchemia acquired the HyACT® technology and Tracey joined as the Chief Scientific Officer and VP of Oncology where she is responsible for the non-clinical and clinical development evaluation of lead compounds from the HyACT® program. Tracey and her team of 15 researchers are based at Monash University where she holds an adjunct Associate Professorship.